Prelude Therapeutics, a Wilmington-based, clinical-stage pharmaceutical company, raised $60 million in a recently closed Series B funding round, the company announced.
The $60 million raised brings to $90 million the amount the company has raised to date, Prelude Therapeutics said in a press release.
Prelude Therapeutics develops small molecule drugs that target the growth of cancer cells.
Prelude’s founder and CEO, Dr. Kris Vaddi, was part of the founding team at Wilmington-based Incyte Corp.
Click here to read the Prelude Therapeutics press release.
The Delaware Division of Small Business wants to help you start or grow your business in Delaware.
Contact us to see how we can help you.